Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB – Get Free Report) Director William Lis sold 8,506 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $25.00, for a total value of $212,650.00. Following the completion of the sale, the director directly owned 41,931 shares in the company, valued at $1,048,275. This represents a 16.86% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
William Lis also recently made the following trade(s):
- On Monday, June 22nd, William Lis sold 7,040 shares of Zai Lab stock. The stock was sold at an average price of $18.09, for a total transaction of $127,353.60.
Zai Lab Stock Up 2.1%
Shares of NASDAQ:ZLAB opened at $26.03 on Friday. Zai Lab Limited Unsponsored ADR has a fifty-two week low of $15.96 and a fifty-two week high of $36.77. The stock has a market cap of $2.96 billion, a price-to-earnings ratio of -15.22 and a beta of 0.78. The firm’s 50 day moving average price is $19.40 and its 200 day moving average price is $19.44.
Institutional Trading of Zai Lab
An institutional investor recently raised its stake in Zai Lab stock. SG Americas Securities LLC raised its holdings in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB – Free Report) by 6.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 10,396 shares of the company’s stock after purchasing an additional 642 shares during the quarter. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 as of its most recent filing with the SEC. 41.65% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
ZLAB has been the subject of several recent analyst reports. Citigroup boosted their target price on Zai Lab from $44.00 to $45.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Weiss Ratings upgraded shares of Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 29th. Zacks Research upgraded shares of Zai Lab from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 7th. Finally, Wall Street Zen downgraded shares of Zai Lab from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Zai Lab presently has a consensus rating of “Moderate Buy” and an average price target of $40.20.
Read Our Latest Report on Zai Lab
About Zai Lab
Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.
The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.
See Also
- Five stocks we like better than Zai Lab
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.
